The company launched a "core" service using Illumina microarray genotyping, and has plans for an expanded NGS offering with Quest Diagnostics.
The developers anticipate that their new approach may enable noninvasive and continuous monitoring of glucose, lactate, and other clinical parameters.
The method uses DESI-MS imaging to analyze fine-needle aspiration biopsies and could help evaluate cases where traditional cytology is inconclusive.
The company has collected initial evidence for an algorithmic method to predict immunotherapy response, and is studying its technology in treatment monitoring.
While clinical lab product revenues were flat year over year, point-of-care sales spiked 29 percent on higher HIV test sales in Africa.
Within Diagnostics, year-over-year core laboratory Q3 revenues rose 8 percent to $1.18 billion but molecular diagnostics revenues fell 8 percent to $111 million.
ACLA filed a motion arguing that HHS' PAMA data collection process is flawed. It follows a July decision that overturned a lower court's dismissal of ACLA's lawsuit.